+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Short Bowel Syndrome Market Research Report by Drug Class (GLP-2, Glutamine, and Growth Hormone), by Region (Americas, Asia-Pacific, and Europe, Middle East & Africa) - Global Forecast to 2026 - Cumulative Impact of COVID-19

  • ID: 4985952
  • Report
  • July 2021
  • Region: Global, North America, Europe, Asia Pacific, Latin America, Middle East, Africa
  • 185 pages
  • 360iResearch™
UP TO OFF
until Sep 30th 2021
The Global Short Bowel Syndrome Market will Grow to USD 2,476.11 Million by 2026, at a CAGR of 19.18%

FEATURED COMPANIES

  • 9 Meters Biopharma, Inc.
  • Ardelyx Inc
  • Merck KGaA
  • Nestlé S.A.,
  • Nutrinia Ltd
  • OxThera AB
The Global Short Bowel Syndrome Market size was estimated at USD 864.06 Million in 2020 and expected to reach USD 1,026.86 Million in 2021, at a Compound Annual Growth Rate (CAGR) 19.18% to reach USD 2,476.11 Million by 2026.



Market Statistics:

The report provides market sizing and forecast across five major currencies - USD, EUR GBP, JPY, and AUD. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2019 are considered historical years, 2020 as the base year, 2021 as the estimated year, and years from 2022 to 2026 are considered the forecast period.

Market Segmentation & Coverage:

This research report categorizes the Short Bowel Syndrome to forecast the revenues and analyze the trends in each of the following sub-markets:
  • Based on Drug Class, the Short Bowel Syndrome Market was examined across GLP-2, Glutamine, and Growth Hormone.
  • Based on Geography, the Short Bowel Syndrome Market was examined across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas was further studied across Argentina, Brazil, Canada, Mexico, and United States. The Asia-Pacific was further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, and Thailand. The Europe, Middle East & Africa was further studied across France, Germany, Italy, Netherlands, Qatar, Russia, Saudi Arabia, South Africa, Spain, United Arab Emirates, and United Kingdom.
Cumulative Impact of COVID-19:

COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. This ongoing research amplifies this research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.

Competitive Strategic Window:

The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix evaluates and categorizes the vendors in the Short Bowel Syndrome Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Market Share Analysis:

The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.

Company Usability Profiles:

The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Short Bowel Syndrome Market, including 9 Meters Biopharma, Inc., Adocia SAS, Ardelyx Inc, AstraZeneca PLC, Emmaus Life Sciences, Inc., Johnson & Johnson Services, Inc., Merck KGaA, Mylan N.V., Naia Pharmaceuticals, Inc., Nestlé S.A.,, Novartis International AG, Nutrinia Ltd, OPKO Health Inc., OxThera AB, Pfizer Inc., PhaseBio Pharmaceuticals Inc., Sancilio & Company Inc, Shire PLC, Swedish Orphan Biovitrum AB, Teva Pharmaceutical Industries Ltd, VectivBio AG, and Zealand Pharma A/S.

The report provides insights on the following pointers:

1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:

1. What is the market size and forecast of the Global Short Bowel Syndrome Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Short Bowel Syndrome Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Short Bowel Syndrome Market?
4. What is the competitive strategic window for opportunities in the Global Short Bowel Syndrome Market?
5. What are the technology trends and regulatory frameworks in the Global Short Bowel Syndrome Market?
6. What is the market share of the leading vendors in the Global Short Bowel Syndrome Market?
7. What modes and strategic moves are considered suitable for entering the Global Short Bowel Syndrome Market?
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • 9 Meters Biopharma, Inc.
  • Ardelyx Inc
  • Merck KGaA
  • Nestlé S.A.,
  • Nutrinia Ltd
  • OxThera AB
1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders

2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary
3.1. Introduction
3.2. Market Outlook
3.3. Drug Class Outlook
3.4. Geography Outlook
3.5. Competitor Outlook

4. Market Overview
4.1. Introduction
4.2. Cumulative Impact of COVID-19

5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Increased prevalence of short bowel syndrome and awareness programs by non-profit organizations
5.1.1.2. Rising efforts in the launch of effective treatments
5.1.1.3. Awareness Programs by Non-Profit Organizations
5.1.2. Restraints
5.1.2.1. Lack of approved treatment options
5.1.2.2. Lethal adverse complications like colonic cancer, polyps along with common side effects associated with the medication
5.1.3. Opportunities
5.1.3.1. Development of short bowel syndrome drugs is at a nascent stage
5.1.3.2. Public-private partnerships are encouraging pharmaceutical companies to develop new orphan drugs for short bowel syndrome
5.1.4. Challenges
5.1.4.1. Awareness among physicians
5.2. Porters Five Forces Analysis
5.2.1. Threat of New Entrants
5.2.2. Threat of Substitutes
5.2.3. Bargaining Power of Customers
5.2.4. Bargaining Power of Suppliers
5.2.5. Industry Rivalry

6. Short Bowel Syndrome Market, by Drug Class
6.1. Introduction
6.2. GLP-2
6.3. Glutamine
6.4. Growth Hormone

7. Americas Short Bowel Syndrome Market
7.1. Introduction
7.2. Argentina
7.3. Brazil
7.4. Canada
7.5. Mexico
7.6. United States

8. Asia-Pacific Short Bowel Syndrome Market
8.1. Introduction
8.2. Australia
8.3. China
8.4. India
8.5. Indonesia
8.6. Japan
8.7. Malaysia
8.8. Philippines
8.9. Singapore
8.10. South Korea
8.11. Thailand

9. Europe, Middle East & Africa Short Bowel Syndrome Market
9.1. Introduction
9.2. France
9.3. Germany
9.4. Italy
9.5. Netherlands
9.6. Qatar
9.7. Russia
9.8. Saudi Arabia
9.9. South Africa
9.10. Spain
9.11. United Arab Emirates
9.12. United Kingdom

10. Competitive Landscape
10.1. FPNV Positioning Matrix
10.1.1. Quadrants
10.1.2. Business Strategy
10.1.3. Product Satisfaction
10.2. Market Ranking Analysis
10.3. Market Share Analysis, By Key Player
10.4. Competitive Scenario
10.4.1. Merger & Acquisition
10.4.2. Agreement, Collaboration, & Partnership
10.4.3. New Product Launch & Enhancement
10.4.4. Investment & Funding
10.4.5. Award, Recognition, & Expansion

11. Company Usability Profiles
11.1. 9 Meters Biopharma, Inc.
11.2. Adocia SAS
11.3. Ardelyx Inc
11.4. AstraZeneca PLC
11.5. Emmaus Life Sciences, Inc.
11.6. Johnson & Johnson Services, Inc.
11.7. Merck KGaA
11.8. Mylan N.V.
11.9. Naia Pharmaceuticals, Inc.
11.10. Nestlé S.A.,
11.11. Novartis International AG
11.12. Nutrinia Ltd
11.13. OPKO Health Inc.
11.14. OxThera AB
11.15. Pfizer Inc.
11.16. PhaseBio Pharmaceuticals Inc.
11.17. Sancilio & Company Inc
11.18. Shire PLC
11.19. Swedish Orphan Biovitrum AB
11.20. Teva Pharmaceutical Industries Ltd
11.21. VectivBio AG
11.22. Zealand Pharma A/S

12. Appendix
12.1. Discussion Guide
12.2. License & Pricing

List of Figures
FIGURE 1. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, 2020 VS 2026 (USD MILLION)
FIGURE 2. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY DRUG CLASS, 2020 (USD MILLION)
FIGURE 3. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY GEOGRAPHY, 2020 (USD MILLION)
FIGURE 4. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, 2018-2026 (USD MILLION)
FIGURE 5. GLOBAL SHORT BOWEL SYNDROME MARKET: MARKET DYNAMICS
FIGURE 6. GLOBAL SHORT BOWEL SYNDROME MARKET: PORTERS FIVE FORCES ANALYSIS
FIGURE 7. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY DRUG CLASS, 2020 VS 2026 (%)
FIGURE 8. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY DRUG CLASS, 2020 VS 2026 (USD MILLION)
FIGURE 9. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY DRUG CLASS, 2026
FIGURE 10. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY GLP-2, 2018-2026 (USD MILLION)
FIGURE 11. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY GLP-2, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
FIGURE 12. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY GLUTAMINE, 2018-2026 (USD MILLION)
FIGURE 13. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY GLUTAMINE, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
FIGURE 14. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY GROWTH HORMONE, 2018-2026 (USD MILLION)
FIGURE 15. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY GROWTH HORMONE, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
FIGURE 16. AMERICAS SHORT BOWEL SYNDROME MARKET SIZE, BY GEOGRAPHY, 2020 VS 2026 (%)
FIGURE 17. AMERICAS SHORT BOWEL SYNDROME MARKET SIZE, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
FIGURE 18. COMPETITIVE STRATEGIC WINDOW FOR AMERICAS SHORT BOWEL SYNDROME MARKET SIZE, BY GEOGRAPHY, 2026
FIGURE 19. ARGENTINA SHORT BOWEL SYNDROME MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
FIGURE 20. BRAZIL SHORT BOWEL SYNDROME MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
FIGURE 21. CANADA SHORT BOWEL SYNDROME MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
FIGURE 22. MEXICO SHORT BOWEL SYNDROME MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
FIGURE 23. UNITED STATES SHORT BOWEL SYNDROME MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
FIGURE 24. ASIA-PACIFIC SHORT BOWEL SYNDROME MARKET SIZE, BY GEOGRAPHY, 2020 VS 2026 (%)
FIGURE 25. ASIA-PACIFIC SHORT BOWEL SYNDROME MARKET SIZE, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
FIGURE 26. COMPETITIVE STRATEGIC WINDOW FOR ASIA-PACIFIC SHORT BOWEL SYNDROME MARKET SIZE, BY GEOGRAPHY, 2026
FIGURE 27. AUSTRALIA SHORT BOWEL SYNDROME MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
FIGURE 28. CHINA SHORT BOWEL SYNDROME MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
FIGURE 29. INDIA SHORT BOWEL SYNDROME MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
FIGURE 30. INDONESIA SHORT BOWEL SYNDROME MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
FIGURE 31. JAPAN SHORT BOWEL SYNDROME MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
FIGURE 32. MALAYSIA SHORT BOWEL SYNDROME MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
FIGURE 33. PHILIPPINES SHORT BOWEL SYNDROME MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
FIGURE 34. SINGAPORE SHORT BOWEL SYNDROME MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
FIGURE 35. SOUTH KOREA SHORT BOWEL SYNDROME MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
FIGURE 36. THAILAND SHORT BOWEL SYNDROME MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
FIGURE 37. EUROPE, MIDDLE EAST & AFRICA SHORT BOWEL SYNDROME MARKET SIZE, BY GEOGRAPHY, 2020 VS 2026 (%)
FIGURE 38. EUROPE, MIDDLE EAST & AFRICA SHORT BOWEL SYNDROME MARKET SIZE, BY GEOGRAPHY, 2020 VS 2026 (USD MILLION)
FIGURE 39. COMPETITIVE STRATEGIC WINDOW FOR EUROPE, MIDDLE EAST & AFRICA SHORT BOWEL SYNDROME MARKET SIZE, BY GEOGRAPHY, 2026
FIGURE 40. FRANCE SHORT BOWEL SYNDROME MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
FIGURE 41. GERMANY SHORT BOWEL SYNDROME MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
FIGURE 42. ITALY SHORT BOWEL SYNDROME MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
FIGURE 43. NETHERLANDS SHORT BOWEL SYNDROME MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
FIGURE 44. QATAR SHORT BOWEL SYNDROME MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
FIGURE 45. RUSSIA SHORT BOWEL SYNDROME MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
FIGURE 46. SAUDI ARABIA SHORT BOWEL SYNDROME MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
FIGURE 47. SOUTH AFRICA SHORT BOWEL SYNDROME MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
FIGURE 48. SPAIN SHORT BOWEL SYNDROME MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
FIGURE 49. UNITED ARAB EMIRATES SHORT BOWEL SYNDROME MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
FIGURE 50. UNITED KINGDOM SHORT BOWEL SYNDROME MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
FIGURE 51. GLOBAL SHORT BOWEL SYNDROME MARKET: FPNV POSITIONING MATRIX
FIGURE 52. GLOBAL SHORT BOWEL SYNDROME MARKET: SHARE, BY KEY PLAYER, 2020
FIGURE 53. COMPETITIVE SCENARIO ANALYSIS IN GLOBAL SHORT BOWEL SYNDROME MARKET, BY TYPE

List of Tables
TABLE 1. GLOBAL SHORT BOWEL SYNDROME MARKET: MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2016–2020
TABLE 3. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, 2018-2026 (USD MILLION)
TABLE 4. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD MILLION)
TABLE 5. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY GLP-2, BY GEOGRAPHY, 2018-2026 (USD MILLION)
TABLE 6. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY GLUTAMINE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
TABLE 7. GLOBAL SHORT BOWEL SYNDROME MARKET SIZE, BY GROWTH HORMONE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
TABLE 8. AMERICAS SHORT BOWEL SYNDROME MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
TABLE 9. AMERICAS SHORT BOWEL SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD MILLION)
TABLE 10. ARGENTINA SHORT BOWEL SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD MILLION)
TABLE 11. BRAZIL SHORT BOWEL SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD MILLION)
TABLE 12. CANADA SHORT BOWEL SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD MILLION)
TABLE 13. MEXICO SHORT BOWEL SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD MILLION)
TABLE 14. UNITED STATES SHORT BOWEL SYNDROME MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
TABLE 15. UNITED STATES SHORT BOWEL SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD MILLION)
TABLE 16. ASIA-PACIFIC SHORT BOWEL SYNDROME MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
TABLE 17. ASIA-PACIFIC SHORT BOWEL SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD MILLION)
TABLE 18. AUSTRALIA SHORT BOWEL SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD MILLION)
TABLE 19. CHINA SHORT BOWEL SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD MILLION)
TABLE 20. INDIA SHORT BOWEL SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD MILLION)
TABLE 21. INDONESIA SHORT BOWEL SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD MILLION)
TABLE 22. JAPAN SHORT BOWEL SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD MILLION)
TABLE 23. MALAYSIA SHORT BOWEL SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD MILLION)
TABLE 24. PHILIPPINES SHORT BOWEL SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD MILLION)
TABLE 25. SINGAPORE SHORT BOWEL SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD MILLION)
TABLE 26. SOUTH KOREA SHORT BOWEL SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD MILLION)
TABLE 27. THAILAND SHORT BOWEL SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD MILLION)
TABLE 28. EUROPE, MIDDLE EAST & AFRICA SHORT BOWEL SYNDROME MARKET SIZE, BY GEOGRAPHY, 2018-2026 (USD MILLION)
TABLE 29. EUROPE, MIDDLE EAST & AFRICA SHORT BOWEL SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD MILLION)
TABLE 30. FRANCE SHORT BOWEL SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD MILLION)
TABLE 31. GERMANY SHORT BOWEL SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD MILLION)
TABLE 32. ITALY SHORT BOWEL SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD MILLION)
TABLE 33. NETHERLANDS SHORT BOWEL SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD MILLION)
TABLE 34. QATAR SHORT BOWEL SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD MILLION)
TABLE 35. RUSSIA SHORT BOWEL SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD MILLION)
TABLE 36. SAUDI ARABIA SHORT BOWEL SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD MILLION)
TABLE 37. SOUTH AFRICA SHORT BOWEL SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD MILLION)
TABLE 38. SPAIN SHORT BOWEL SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD MILLION)
TABLE 39. UNITED ARAB EMIRATES SHORT BOWEL SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD MILLION)
TABLE 40. UNITED KINGDOM SHORT BOWEL SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2026 (USD MILLION)
TABLE 41. GLOBAL SHORT BOWEL SYNDROME MARKET: SCORES
TABLE 42. GLOBAL SHORT BOWEL SYNDROME MARKET: BUSINESS STRATEGY
TABLE 43. GLOBAL SHORT BOWEL SYNDROME MARKET: PRODUCT SATISFACTION
TABLE 44. GLOBAL SHORT BOWEL SYNDROME MARKET: RANKING
TABLE 45. GLOBAL SHORT BOWEL SYNDROME MARKET: SHARE, BY KEY PLAYER, 2020
TABLE 46. GLOBAL SHORT BOWEL SYNDROME MARKET: MERGER & ACQUISITION
TABLE 47. GLOBAL SHORT BOWEL SYNDROME MARKET: AGREEMENT, COLLABORATION, & PARTNERSHIP
TABLE 48. GLOBAL SHORT BOWEL SYNDROME MARKET: NEW PRODUCT LAUNCH & ENHANCEMENT
TABLE 49. GLOBAL SHORT BOWEL SYNDROME MARKET: INVESTMENT & FUNDING
TABLE 50. GLOBAL SHORT BOWEL SYNDROME MARKET: AWARD, RECOGNITION, & EXPANSION
TABLE 51. GLOBAL SHORT BOWEL SYNDROME MARKET: LICENSE & PRICING
Note: Product cover images may vary from those shown
  • 9 Meters Biopharma, Inc.
  • Adocia SAS
  • Ardelyx Inc
  • AstraZeneca PLC
  • Emmaus Life Sciences, Inc.
  • Johnson & Johnson Services, Inc.
  • Merck KGaA
  • Mylan N.V.
  • Naia Pharmaceuticals, Inc.
  • Nestlé S.A.,
  • Novartis International AG
  • Nutrinia Ltd
  • OPKO Health Inc.
  • OxThera AB
  • Pfizer Inc.
  • PhaseBio Pharmaceuticals Inc.
  • Sancilio & Company Inc
  • Shire PLC
  • Swedish Orphan Biovitrum AB
  • Teva Pharmaceutical Industries Ltd
  • VectivBio AG
  • Zealand Pharma A/S
Note: Product cover images may vary from those shown

Loading
LOADING...

Adroll
adroll